NEXT
Sign in to follow
Search Results

0 results for 'Venable'

You can use to get even better search results
July 30, 2012 | National Law Journal

MOVERS

Ferdinand Gallo joins the Bingham McCutchen's real estate practice group as partner in the New York office. Plus more law firm movers in this week's column.
4 minute read
July 13, 2012 | Daily Report Online

Freeh report highlights serious governance lapses at Penn State

Where did corporate governance at Penn State go wrong?
7 minute read
February 03, 2012 | The American Lawyer

The Churn: Lateral Moves and Promotions in The Am Law 200

8 minute read
May 07, 2007 | National Law Journal

2007 D.C. 20 � Ranked by D.C. Revenue

8 minute read
December 01, 2011 | Corporate Counsel

Deals & Suits

22 minute read
Fosamax Plaintiffs Lawyer: Mistrial a 'Shock' to Merck
Publication Date: 2009-09-11
Practice Area:
Industry:
Court:
Judge:
Attorneys:
For plaintiff:
For defendant:
Case number:

It wasn't a big surprise that the jury couldn't reach a verdict two days after one juror complained of physical threats in the jury room. But lead counsel for the 71-year-old plaintiff told us Merck ought to be worried about what the mistrial portends for the 900 other Fosamax cases it faces, given that pretrial rulings limited the evidence he was permitted to present.

June 29, 2000 | Law.com

It's a Wonderful Life

To no one's great surprise, the top firms in Washington, D.C., got bigger and richer last year. In some cases, a whole lot richer. The most extreme example is the D.C. office of New York's Skadden, Arps, Slate, Meagher & Flom, where per-partner profits soared to $1.4 million from $1 million in 1998.
11 minute read
September 21, 2012 | New Jersey Law Journal

License Revocation Order Pursuant to Rule 1:28-2(c)

Notice to the bar.
36 minute read
Merck Fails to Knock Out Third Fosamax Test Case
Publication Date: 2010-02-01
Practice Area:
Industry:
Court:
Judge:
Attorneys:
For plaintiff:
For defendant:
Case number:

Will the third time be the charm for plaintiffs who claim Merck's osteoporosis drug caused crippling damage to their jaws? Thanks to Manhattan federal judge John Keenan's refusal to grant Merck's motion to dismiss, we'll find out at a trial beginning in April.

More from ALM

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

Resources

  • Driving Value with Better Decision-Making: A Governance Maturity Checklist

    Brought to you by Diligent Corporation

    Download Now

  • Strategic Triumph: Unveiling the Secrets Behind Small Law Firms Thriving with AI Research and Drafting

    Brought to you by LexisNexis®

    Download Now

  • CFIUS Compliance: Your Organization's Growth and Investment Strategy May Be a Matter of National Security

    Brought to you by HaystackID

    Download Now

  • Document Review Challenges: Strategies for Law Firm Litigation Professionals in 2024

    Brought to you by Integreon

    Download Now